Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$6.04
−$0.25 · -3.97%
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Regular session
$6.04
−$0.25 · -3.97%
Regular session · ET · Market data may be delayed.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Day range
Current $6.04
52-week range
Current $6.04
Regular session · ET · Market data may be delayed.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. Its products include cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Bothell, WA.
Day range
Current $6.04
52-week range
Current $6.04
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 228K USD | 229K USD | — | — | — |
| Gross profit | −228K USD | −229K USD | — | — | — |
| Research and development | 22.96M USD | 22.82M USD | 15.81M USD | 30.08M USD | 23.97M USD |
| Selling, general, and administrative | 31.87M USD | 16.25M USD | 11.44M USD | 10.72M USD | 9.13M USD |
| Operating expenses | 54.65M USD | 38.84M USD | 27.25M USD | 40.8M USD | 33.09M USD |
| Interest income | 1.5M USD | 2.36M USD | 825K USD | 199K USD | 17K USD |
| Interest expense | 819K USD | 2.18M USD | 2.85M USD | 1.79M USD | — |
| Depreciation and amortization | 228K USD | 229K USD | 228K USD | 236K USD | 250K USD |
| Operating income | −54.88M USD | −39.07M USD | −27.25M USD | −40.8M USD | −33.09M USD |
| Net income | −54.65M USD | −39.83M USD | −29.82M USD | −42.35M USD | −33.15M USD |
Company facts updated Nov 13, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.25
152.48% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI14.28M0.13%10.42B USD0.35%$148.7-1.65%
iShares Russell 2000 ETFIWM13M0.02%76.57B USD0.19%$277.32-0.40%
Simplify Propel Opportunities ETFSURI6.01M7.81%70.38M USD2.84%$16.54+2.48%
iShares Russell 2000 Growth ETFIWO4.8M0.03%13.97B USD0.24%$349.84-0.60%
iShares Micro-Cap ETFIWC1.52M0.12%1.21B USD0.60%$173.87-0.69%
iShares Core S&P Total U.S. Stock Market ETFITOT934.69K0.00%96.05B USD0.03%$164.91-0.16%
Virtus Biotech Clinical Trials ETFBBC292.44K0.86%31.61M USD0.65%$42.4523-1.59%
iShares Russell 2500 ETFSMMD288.25K0.01%4.21B USD0.23%$86.725-0.14%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMSimplify Propel Opportunities ETFSURIiShares Russell 2000 Growth ETFIWOiShares Micro-Cap ETFIWCiShares Core S&P Total U.S. Stock Market ETFITOTVirtus Biotech Clinical Trials ETFBBCiShares Russell 2500 ETFSMMDAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
